Anixa Biosciences (NASDAQ:ANIX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Anixa Biosciences (NASDAQ:ANIX) posted its earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02, Zacks reports.

Anixa Biosciences Price Performance

Shares of NASDAQ:ANIX opened at $2.25 on Friday. The business’s 50 day moving average price is $2.94 and its 200-day moving average price is $3.02. Anixa Biosciences has a 1 year low of $2.14 and a 1 year high of $5.13. The firm has a market capitalization of $72.40 million, a price-to-earnings ratio of -5.77 and a beta of 0.90.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, November 19th.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.